NCT06676722View on ClinicalTrials.gov

SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 5, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Nasopharyngeal Cancinoma (NPC)SBRTImmunotherapy
Interventions
DRUG

SBRT combined with Nimotuzumab followed by Tislelizumab

BRT combined with 3 cycles of Nimotuzumab 400mg qw followed by maintain Tislelizumab for 2 years or until disease progression

Trial Locations (2)

361003

ENROLLING_BY_INVITATION

The First Affiliated Hospital of Xiamen University, Xiamen

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER